Published in Curr Opin Lipidol on June 01, 2001
Pioglitazone attenuates mitochondrial dysfunction, cognitive impairment, cortical tissue loss, and inflammation following traumatic brain injury. Exp Neurol (2010) 1.04
Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects. Am Heart J (2012) 0.98
Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes. Vasc Health Risk Manag (2013) 0.94
Agonism of Peroxisome Proliferator Receptor-Gamma may have Therapeutic Potential for Neuroinflammation and Parkinson's Disease. Curr Neuropharmacol (2007) 0.94
Effects of Endogenous PPAR Agonist Nitro-Oleic Acid on Metabolic Syndrome in Obese Zucker Rats. PPAR Res (2010) 0.90
Proteome analysis identified the PPARγ ligand 15d-PGJ2 as a novel drug inhibiting melanoma progression and interfering with tumor-stroma interaction. PLoS One (2012) 0.89
Studies of gene variants related to inflammation, oxidative stress, dyslipidemia, and obesity: implications for a nutrigenetic approach. J Obes (2011) 0.89
Expression of a peroxisome proliferator-activated receptor gene (xPPARalpha) from Xenopus laevis in tobacco (Nicotiana tabacum) plants. Planta (2006) 0.87
Peroxisome proliferator-activated receptor {delta} activators induce IL-8 expression in nonstimulated endothelial cells in a transcriptional and posttranscriptional manner. J Biol Chem (2010) 0.83
Resveratrol and its metabolites bind to PPARs. Chembiochem (2014) 0.83
Mutation screen and association studies in the diacylglycerol O-acyltransferase homolog 2 gene (DGAT2), a positional candidate gene for early onset obesity on chromosome 11q13. BMC Genet (2007) 0.81
Significance of anti-inflammatory effects of PPARgamma agonists? Gut (2006) 0.80
Correction of dysfunctional fatty acid metabolism using peroxisome proliferator activated receptor gamma agonists. J R Soc Med (2002) 0.79
Nonhuman primates and other animal models in diabetes research. J Diabetes Sci Technol (2012) 0.79
Inhibition of Dexamethasone-induced Fatty Liver Development by Reducing miR-17-5p Levels. Mol Ther (2015) 0.77
55-week treatment of mice with the unani and ayurvedic medicine pomegranate flower ameliorates ageing-associated insulin resistance and skin abnormalities. Evid Based Complement Alternat Med (2011) 0.77
Peroxisome proliferator-activated receptor (PPAR) α and δ activators induce ICAM-1 expression in quiescent non stimulated endothelial cells. J Inflamm (Lond) (2016) 0.75
Carvacrol ameliorates the PPAR-A and cytochrome P450 expression on D-galactosamine induced hepatotoxicity rats. Afr J Tradit Complement Altern Med (2014) 0.75
Lipoprotein kinetics in the metabolic syndrome: pathophysiological and therapeutic lessons from stable isotope studies. Clin Biochem Rev (2004) 0.75
Nitrooleic Acid Attenuates Lipid Metabolic Disorders and Liver Steatosis in DOCA-Salt Hypertensive Mice. PPAR Res (2015) 0.75
An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science (2001) 8.73
The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem (1997) 4.55
Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation (1998) 4.39
PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med (2001) 4.17
PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J (1996) 4.11
Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem (1999) 3.57
Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature (1998) 3.48
Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res (1996) 3.36
Protective role of interleukin-10 in atherosclerosis. Circ Res (1999) 3.28
Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J Biol Chem (1998) 3.27
Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat Med (1998) 3.13
Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res (2000) 3.02
The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta (1996) 2.83
Transient increase in obese gene expression after food intake or insulin administration. Nature (1995) 2.79
Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol (2001) 2.66
Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J Clin Oncol (2001) 2.51
Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem (2000) 2.18
Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor alpha-deficient mice. J Biol Chem (1997) 2.18
Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11beta-hydroxysteroid dehydrogenase type 1 null mice. J Biol Chem (2001) 2.11
Regulation of peroxisome proliferator-activated receptor gamma expression by adipocyte differentiation and determination factor 1/sterol regulatory element binding protein 1: implications for adipocyte differentiation and metabolism. Mol Cell Biol (1999) 2.05
Induction of IkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators. J Biol Chem (2000) 1.95
Somatic gene transfer of human ApoA-I inhibits atherosclerosis progression in mouse models. Circulation (1999) 1.88
Expression of the peroxisome proliferator-activated receptor alpha gene is stimulated by stress and follows a diurnal rhythm. J Biol Chem (1996) 1.88
Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. J Clin Invest (1995) 1.88
Bcl-2 protein expression in follicular lymphomas in absence of 14;18 translocation. Lancet (1990) 1.86
Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators. J Biol Chem (1997) 1.84
Peroxisome proliferator-activated receptors, orphans with ligands and functions. Curr Opin Lipidol (1997) 1.82
Cigarette smoking is associated with unhealthy patterns of nutrient intake: a meta-analysis. J Nutr (1998) 1.74
Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J Clin Invest (1995) 1.74
p300 interacts with the N- and C-terminal part of PPARgamma2 in a ligand-independent and -dependent manner, respectively. J Biol Chem (1999) 1.66
Induction of the acyl-coenzyme A synthetase gene by fibrates and fatty acids is mediated by a peroxisome proliferator response element in the C promoter. J Biol Chem (1995) 1.66
CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. Circulation (2000) 1.65
The orphan nuclear receptor ROR alpha is a negative regulator of the inflammatory response. EMBO Rep (2001) 1.64
Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr Opin Lipidol (1999) 1.62
Expression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPARalpha, PPARgamma, and LXR. Biochem Biophys Res Commun (2004) 1.61
Variation in the PPARalpha gene is associated with altered function in vitro and plasma lipid concentrations in Type II diabetic subjects. Diabetologia (2000) 1.54
Induction of ob gene expression by corticosteroids is accompanied by body weight loss and reduced food intake. J Biol Chem (1995) 1.54
Transcriptional control of adipogenesis. Curr Opin Cell Biol (1998) 1.52
Leptin. Lancet (1998) 1.51
PPAR-alpha-null mice are protected from high-fat diet-induced insulin resistance. Diabetes (2001) 1.50
Schistosoma mansoni schistosomula reduce E-selectin and VCAM-1 expression in TNF-alpha-stimulated lung microvascular endothelial cells by interfering with the NF-kappaB pathway. Eur J Immunol (1999) 1.49
LAZ3 rearrangements in non-Hodgkin's lymphoma: correlation with histology, immunophenotype, karyotype, and clinical outcome in 217 patients. Blood (1994) 1.48
Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. J Clin Invest (2001) 1.47
Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol (2002) 1.47
Apolipoprotein A-I containing lipoproteins in coronary artery disease. Atherosclerosis (1987) 1.47
Differential electroimmunoassay of human LpA-I lipoprotein particles on ready-to-use plates. Clin Chem (1990) 1.46
Regulation of the peroxisome proliferator-activated receptor alpha gene by glucocorticoids. J Biol Chem (1994) 1.45
PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases. Biochem Soc Trans (2006) 1.44
An easier, reproducible, and mass-production method to study the blood-brain barrier in vitro. J Neurochem (1990) 1.43
Potential gene therapy for lecithin-cholesterol acyltransferase (LCAT)-deficient and hypoalphalipoproteinemic patients with adenovirus-mediated transfer of human LCAT gene. Circulation (1996) 1.43
Lipid traffic between high density lipoproteins and Plasmodium falciparum-infected red blood cells. J Cell Biol (1991) 1.43
The use of monoclonal antibodies to localize the low density lipoprotein receptor-binding domain of apolipoprotein B. J Biol Chem (1989) 1.41
The utility of mitotic index, oestrogen receptor and Ki-67 measurements in the creation of novel prognostic indices for node-negative breast cancer. Eur J Surg Oncol (1999) 1.40
Peroxisome proliferator-activated receptors in reproductive tissues: from gametogenesis to parturition. J Endocrinol (2006) 1.40
The OSBP-related protein family in humans. J Lipid Res (2001) 1.40
Adult onset Still's disease and pregnancy. J Rheumatol (1993) 1.39
Protection against atherogenesis in mice mediated by human apolipoprotein A-IV. Science (1996) 1.39
Distribution of lipid variables in subjects in Belfast, Northern Ireland and Taiyuan, P R China. Atherosclerosis (1993) 1.39
The nuclear receptors peroxisome proliferator-activated receptor alpha and Rev-erbalpha mediate the species-specific regulation of apolipoprotein A-I expression by fibrates. J Biol Chem (1998) 1.38
PPARgamma3 mRNA: a distinct PPARgamma mRNA subtype transcribed from an independent promoter. FEBS Lett (1998) 1.38
The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. Diabetes Obes Metab (2005) 1.37
Liver X receptor activation controls intracellular cholesterol trafficking and esterification in human macrophages. Circ Res (2005) 1.37
Peroxisome proliferator-activated receptor gamma activators affect the maturation of human monocyte-derived dendritic cells. Eur J Immunol (2001) 1.36
Peroxisome proliferator-activated receptor gamma is induced during differentiation of colon epithelium cells. J Endocrinol (1999) 1.35
Severe atherosclerosis and hypoalphalipoproteinemia in the staggerer mouse, a mutant of the nuclear receptor RORalpha. Circulation (1998) 1.35
Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CI, CII, CIII, and E. Arterioscler Thromb Vasc Biol (1995) 1.35
Peroxisome proliferator-activated receptor-alpha regulates lipid homeostasis, but is not associated with obesity: studies with congenic mouse lines. J Biol Chem (2001) 1.34
Drug transfer across the blood-brain barrier: correlation between in vitro and in vivo models. J Neurochem (1992) 1.32
Cholesterol efflux from cultured adipose cells is mediated by LpAI particles but not by LpAI:AII particles. Biochem Biophys Res Commun (1987) 1.30
Use of bacterial expression cloning to localize the epitopes for a series of monoclonal antibodies against apolipoprotein B100. J Biol Chem (1990) 1.30
Human ABCA1 BAC transgenic mice show increased high density lipoprotein cholesterol and ApoAI-dependent efflux stimulated by an internal promoter containing liver X receptor response elements in intron 1. J Biol Chem (2001) 1.28
Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma. J Clin Invest (1996) 1.28
Abundant adrenal-specific transcription of the human P450c21A "pseudogene". J Biol Chem (1993) 1.28
Oxidized phospholipids activate PPARalpha in a phospholipase A2-dependent manner. FEBS Lett (2000) 1.28
Cloning and sequencing of cDNAs encoding the human hepatocyte nuclear factor 4 indicate the presence of two isoforms in human liver. Gene (1994) 1.26